Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Ascher-Svanum, H.
193  Ergebnisse:
Personensuche X
?
1

Cost Implications Of Early Discontinuation And Restart Of I..:

Ascher-Svanum, H. ; Lage, M.J. ; Perez, M....
Value in Health.  17 (2014)  3 - p. A264 , 2014
Link: https://doi.org/10.1016/..
 
?
2

Review of the usual treatment of adults with type 2 diabete..:

Katada, A. ; Ascher-Svanum, H.
Value in Health.  17 (2014)  3 - p. A262 , 2014
Link: https://doi.org/10.1016/..
 
?
3

Increased Burden On Primary Care Physicians Preceding Diagn..:

Chen, L. ; Reed, C. ; Happich, M....
Value in Health.  16 (2013)  3 - p. A201 , 2013
Link: https://doi.org/10.1016/..
 
?
4

Effectiveness of olanzapine in the treatment of symptomatic..:

Montgomery, W. ; Ye, W.W. ; Kadziola, Z....
Value in Health.  16 (2013)  3 - p. A55 , 2013
Link: https://doi.org/10.1016/..
 
?
5

PMH5 Does Participation in a Weight Control Program Also Im..:

Montgomery, W. ; Treuer, T. ; Ye, W.W....
Value in Health.  15 (2012)  7 - p. A669 , 2012
Link: https://doi.org/10.1016/..
 
?
6

PMH12 Risk of Relapse and Hospitalization in the 2-Year Ope..:

Novick, D. ; Ascher-Svanum, H. ; Bertsch, J....
Value in Health.  14 (2011)  7 - p. A288-A289 , 2011
Link: https://doi.org/10.1016/..
 
?
7

PMH13 Differences Between Patients Undergoing Augmentation ..:

Ascher-Svanum, H. ; Brnabic, A.J. ; Lawson, T....
Value in Health.  14 (2011)  7 - p. A289 , 2011
Link: https://doi.org/10.1016/..
 
?
8

PMH5 Empirically-Driven Definitions of "Good" "Moderate" an..:

Ascher-Svanum, H. ; Novick, D. ; Haro, J....
Value in Health.  14 (2011)  7 - p. A287 , 2011
Link: https://doi.org/10.1016/..
 
?
9

PMH4 Extent of Attaining and Maintaining Symptom Remission ..:

Levine, S.Z. ; Rabinowitz, J. ; Ascher-Svanum, H...
Value in Health.  14 (2011)  7 - p. A287 , 2011
Link: https://doi.org/10.1016/..
 
?
10

PMH3 Olanzapine Long-Acting Injection for Schizophrenia: An..:

Novick, D. ; Anand, H. ; Ascher-Svanum, H....
Value in Health.  14 (2011)  7 - p. A287 , 2011
Link: https://doi.org/10.1016/..
 
?
11

PMH51 THE COST-EFFECTIVENESS OF EARLY RESPONDERS VERSUS EAR..:

Peng, X ; Ascher-Svanum, H ; Faries, D...
Value in Health.  13 (2010)  3 - p. A113-A114 , 2010
Link: https://doi.org/10.1016/..
 
?
12

PMH9 PATIENTS' EARLY PERCEPTIONS OF MEDICATIONS' BENEFITS P..:

Nyhuis, A ; Ascher-Svanum, H ; Faries, D...
Value in Health.  13 (2010)  3 - p. A105 , 2010
Link: https://doi.org/10.1016/..
 
?
13

PMH17 OUTCOME TRAJECTORIES IN THE LONG-TERM TREATMENT OF SC..:

Milton, D ; Cuyun Carter, G ; Faries, D.
Value in Health.  13 (2010)  3 - p. A107 , 2010
Link: https://doi.org/10.1016/..
 
?
14

The heterogeneity of antipsychotic response in the treatmen..:

Case, M. ; Stauffer, V. L. ; Ascher-Svanum, H....
Psychological Medicine.  41 (2010)  6 - p. 1291-1300 , 2010
Link: https://doi.org/10.1017/..
 
?
15

PMH66 REASONS FOR CONTINUING OR DISCONTINUING OLANZAPINE IN..:

Chen, J ; Ascher-Svanum, H ; Case, MG...
Value in Health.  13 (2010)  3 - p. A117 , 2010
Link: https://doi.org/10.1016/..
 
1-15